vs

Side-by-side financial comparison of Immunocore Holdings plc (IMCR) and JBG SMITH Properties (JBGS). Click either name above to swap in a different company.

JBG SMITH Properties is the larger business by last-quarter revenue ($127.6M vs $104.5M, roughly 1.2× Immunocore Holdings plc). On growth, Immunocore Holdings plc posted the faster year-over-year revenue change (24.3% vs -2.5%). Over the past eight quarters, Immunocore Holdings plc's revenue compounded faster (21.7% CAGR vs -6.3%).

Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.

JBG SMITH Properties is a publicly traded real estate investment trust based in Bethesda, Maryland.

IMCR vs JBGS — Head-to-Head

Bigger by revenue
JBGS
JBGS
1.2× larger
JBGS
$127.6M
$104.5M
IMCR
Growing faster (revenue YoY)
IMCR
IMCR
+26.8% gap
IMCR
24.3%
-2.5%
JBGS
Faster 2-yr revenue CAGR
IMCR
IMCR
Annualised
IMCR
21.7%
-6.3%
JBGS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IMCR
IMCR
JBGS
JBGS
Revenue
$104.5M
$127.6M
Net Profit
$-45.5M
Gross Margin
97.4%
Operating Margin
-18.8%
-47.5%
Net Margin
-35.7%
Revenue YoY
24.3%
-2.5%
Net Profit YoY
24.0%
EPS (diluted)
$-0.61
$-0.76

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMCR
IMCR
JBGS
JBGS
Q4 25
$104.5M
$127.6M
Q3 25
$103.7M
$123.9M
Q2 25
$98.0M
$126.5M
Q1 25
$93.9M
$120.7M
Q4 24
$84.1M
$130.8M
Q3 24
$80.2M
$136.0M
Q2 24
$75.4M
$135.3M
Q1 24
$70.5M
$145.2M
Net Profit
IMCR
IMCR
JBGS
JBGS
Q4 25
$-45.5M
Q3 25
$-177.0K
$-28.6M
Q2 25
$-10.3M
$-19.2M
Q1 25
$5.0M
$-45.7M
Q4 24
$-59.9M
Q3 24
$8.7M
$-27.0M
Q2 24
$-11.6M
$-24.4M
Q1 24
$-24.4M
$-32.3M
Gross Margin
IMCR
IMCR
JBGS
JBGS
Q4 25
97.4%
Q3 25
99.5%
Q2 25
98.9%
Q1 25
99.1%
Q4 24
99.6%
Q3 24
99.4%
Q2 24
97.7%
Q1 24
99.7%
Operating Margin
IMCR
IMCR
JBGS
JBGS
Q4 25
-18.8%
-47.5%
Q3 25
-6.9%
-27.5%
Q2 25
-15.2%
-18.4%
Q1 25
-3.9%
-44.7%
Q4 24
-23.1%
-53.6%
Q3 24
-10.6%
-22.4%
Q2 24
-21.2%
-24.3%
Q1 24
-37.6%
-30.1%
Net Margin
IMCR
IMCR
JBGS
JBGS
Q4 25
-35.7%
Q3 25
-0.2%
-23.1%
Q2 25
-10.5%
-15.2%
Q1 25
5.4%
-37.9%
Q4 24
-45.8%
Q3 24
10.9%
-19.8%
Q2 24
-15.4%
-18.0%
Q1 24
-34.7%
-22.2%
EPS (diluted)
IMCR
IMCR
JBGS
JBGS
Q4 25
$-0.61
$-0.76
Q3 25
$0.00
$-0.48
Q2 25
$-0.20
$-0.29
Q1 25
$0.10
$-0.56
Q4 24
$-0.47
$-0.70
Q3 24
$0.17
$-0.32
Q2 24
$-0.23
$-0.27
Q1 24
$-0.49
$-0.36

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMCR
IMCR
JBGS
JBGS
Cash + ST InvestmentsLiquidity on hand
$864.2M
$75.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$381.0M
$1.2B
Total Assets
$1.1B
$4.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMCR
IMCR
JBGS
JBGS
Q4 25
$864.2M
$75.3M
Q3 25
$892.4M
$64.4M
Q2 25
$882.8M
$61.4M
Q1 25
$837.0M
$81.3M
Q4 24
$820.4M
$145.8M
Q3 24
$901.3M
$137.0M
Q2 24
$859.6M
$163.5M
Q1 24
$832.8M
$220.5M
Total Debt
IMCR
IMCR
JBGS
JBGS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$438.7M
Q2 24
$452.5M
Q1 24
$452.5M
Stockholders' Equity
IMCR
IMCR
JBGS
JBGS
Q4 25
$381.0M
$1.2B
Q3 25
$396.6M
$1.2B
Q2 25
$388.5M
$1.3B
Q1 25
$378.5M
$1.6B
Q4 24
$360.7M
$1.8B
Q3 24
$377.8M
$1.9B
Q2 24
$359.1M
$2.0B
Q1 24
$359.5M
$2.1B
Total Assets
IMCR
IMCR
JBGS
JBGS
Q4 25
$1.1B
$4.4B
Q3 25
$1.1B
$4.4B
Q2 25
$1.1B
$4.5B
Q1 25
$1.0B
$4.7B
Q4 24
$1.0B
$5.0B
Q3 24
$1.1B
$5.2B
Q2 24
$1.0B
$5.3B
Q1 24
$994.0M
$5.4B
Debt / Equity
IMCR
IMCR
JBGS
JBGS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
1.16×
Q2 24
1.26×
Q1 24
1.26×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMCR
IMCR
JBGS
JBGS
Operating Cash FlowLast quarter
$-32.7M
$73.3M
Free Cash FlowOCF − Capex
$-35.5M
FCF MarginFCF / Revenue
-34.0%
Capex IntensityCapex / Revenue
2.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-15.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMCR
IMCR
JBGS
JBGS
Q4 25
$-32.7M
$73.3M
Q3 25
$-4.5M
$8.9M
Q2 25
$26.0M
$18.8M
Q1 25
$435.0K
$12.9M
Q4 24
$-14.0M
$129.4M
Q3 24
$21.1M
$26.4M
Q2 24
$23.5M
$23.8M
Q1 24
$-4.6M
$37.0M
Free Cash Flow
IMCR
IMCR
JBGS
JBGS
Q4 25
$-35.5M
Q3 25
$-5.2M
Q2 25
$25.6M
Q1 25
$137.0K
Q4 24
$-17.5M
Q3 24
$20.3M
Q2 24
$23.1M
Q1 24
$-5.0M
FCF Margin
IMCR
IMCR
JBGS
JBGS
Q4 25
-34.0%
Q3 25
-5.0%
Q2 25
26.1%
Q1 25
0.1%
Q4 24
-20.9%
Q3 24
25.3%
Q2 24
30.7%
Q1 24
-7.1%
Capex Intensity
IMCR
IMCR
JBGS
JBGS
Q4 25
2.8%
Q3 25
0.7%
Q2 25
0.4%
Q1 25
0.3%
Q4 24
4.3%
Q3 24
1.0%
Q2 24
0.4%
Q1 24
0.6%
Cash Conversion
IMCR
IMCR
JBGS
JBGS
Q4 25
Q3 25
Q2 25
Q1 25
0.09×
Q4 24
Q3 24
2.42×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons